US Biologic

US BIOLOGIC, headquartered in the Memphis Medical District, specializes in developing oral vaccines to address Lyme disease, pet health concerns, and antimicrobial resistance in poultry and livestock. The company operates in the animal health and public health sectors, targeting both domestic and international markets. US BIOLOGIC's primary clients include veterinary professionals, livestock producers, and public health organizations. The business model revolves around the research, development, and commercialization of proprietary oral vaccines, generating revenue through product sales and strategic partnerships. Recent collaborations, such as with JP McHale, aim to expand their workforce and market reach. The company's innovative solutions are crucial in preventing zoonotic diseases, which are diseases that can be transmitted from animals to humans, thereby enhancing global health security. By focusing on preventive measures, US BIOLOGIC contributes to reducing the economic and human toll of infectious diseases.

Keywords: oral vaccines, Lyme disease, pet health, antimicrobial resistance, livestock, zoonotic diseases, veterinary, public health, innovation, partnerships.